BR112012011710A2 - composto de espiropiperidina como antagonistas de receptor de orl-1, sua composição farmacêutica e seu uso - Google Patents

composto de espiropiperidina como antagonistas de receptor de orl-1, sua composição farmacêutica e seu uso

Info

Publication number
BR112012011710A2
BR112012011710A2 BR112012011710A BR112012011710A BR112012011710A2 BR 112012011710 A2 BR112012011710 A2 BR 112012011710A2 BR 112012011710 A BR112012011710 A BR 112012011710A BR 112012011710 A BR112012011710 A BR 112012011710A BR 112012011710 A2 BR112012011710 A2 BR 112012011710A2
Authority
BR
Brazil
Prior art keywords
orl
receptor antagonists
pharmaceutical composition
treatment
spiropiperidine compound
Prior art date
Application number
BR112012011710A
Other languages
English (en)
Portuguese (pt)
Inventor
Alma Maria Jimenez-Aguado
Ana Belen Benito Collado
Celia Lafuente Blanco
Concepcion Pedregal-Tercero
Maria Angeles Martinez-Grau
Miguel Angel Toledo Escribano
Nuria Diaz Buezo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112012011710A2 publication Critical patent/BR112012011710A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112012011710A 2009-11-16 2010-11-12 composto de espiropiperidina como antagonistas de receptor de orl-1, sua composição farmacêutica e seu uso BR112012011710A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382245 2009-11-16
US29862810P 2010-01-27 2010-01-27
PCT/US2010/056449 WO2011060217A1 (en) 2009-11-16 2010-11-12 Spiropiperidine compounds as orl-1 receptor antagonists

Publications (1)

Publication Number Publication Date
BR112012011710A2 true BR112012011710A2 (pt) 2016-03-01

Family

ID=41800752

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012011710A BR112012011710A2 (pt) 2009-11-16 2010-11-12 composto de espiropiperidina como antagonistas de receptor de orl-1, sua composição farmacêutica e seu uso

Country Status (18)

Country Link
US (1) US20120214784A1 (cg-RX-API-DMAC7.html)
EP (1) EP2501704B1 (cg-RX-API-DMAC7.html)
JP (1) JP5723381B2 (cg-RX-API-DMAC7.html)
KR (1) KR101368130B1 (cg-RX-API-DMAC7.html)
CN (1) CN102666550B (cg-RX-API-DMAC7.html)
AU (1) AU2010319400B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012011710A2 (cg-RX-API-DMAC7.html)
CA (1) CA2781041C (cg-RX-API-DMAC7.html)
DK (1) DK2501704T3 (cg-RX-API-DMAC7.html)
EA (1) EA020391B1 (cg-RX-API-DMAC7.html)
ES (1) ES2436241T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20130969T1 (cg-RX-API-DMAC7.html)
MX (1) MX2012005690A (cg-RX-API-DMAC7.html)
PL (1) PL2501704T3 (cg-RX-API-DMAC7.html)
PT (1) PT2501704E (cg-RX-API-DMAC7.html)
RS (1) RS53017B (cg-RX-API-DMAC7.html)
SI (1) SI2501704T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011060217A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104193761B (zh) 2009-12-04 2017-10-17 桑诺维恩药品公司 多环化合物及其使用方法
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之orl-1受體拮抗劑
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
SG10202100724UA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
EP3497101B1 (de) 2016-08-10 2020-12-30 Bayer CropScience Aktiengesellschaft Substituierte 2-heterocyclyl-imidazolyl-carboxamide als schädlingsbekämpfungsmittel
EP3582815A1 (en) 2017-02-16 2019-12-25 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
LT3589638T (lt) 2017-03-02 2021-06-10 Eli Lilly And Company Junginiai, naudingi ror-gama-t slopinimui
DK3589637T3 (da) * 2017-03-02 2021-06-14 Lilly Co Eli Forbindelser, der er anvendelige til inhibering af ROR-GAMMA-T
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
SG11202007823PA (en) 2018-02-16 2020-09-29 Sunovion Pharmaceuticals Inc Salts, crystal forms, and production methods thereof
LT3897833T (lt) 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
EP3766879A1 (en) 2019-07-19 2021-01-20 Basf Se Pesticidal pyrazole derivatives
KR20230003503A (ko) 2020-04-14 2023-01-06 선오비온 파마슈티컬스 인코포레이티드 신경학적 및 정신의학적 장애의 치료를 위한 (S)-(4,5-디히드로-7H-티에노[2,3-c]피란-7-일)-N-메틸메탄아민
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
CN119343353A (zh) * 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003095427A1 (en) 2002-05-10 2003-11-20 Taisho Pharmaceutical Co.,Ltd. Spiro-ring compound
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
WO2005092858A2 (en) * 2004-03-29 2005-10-06 Pfizer Japan Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2522669B1 (en) * 2005-06-02 2016-12-28 Janssen Pharmaceutica NV 3-Spirocyclic indolyl derivatives useful as ORL-1 receptor modulators

Also Published As

Publication number Publication date
WO2011060217A1 (en) 2011-05-19
JP5723381B2 (ja) 2015-05-27
CN102666550B (zh) 2015-07-15
EA201290355A1 (ru) 2012-10-30
EP2501704A1 (en) 2012-09-26
PT2501704E (pt) 2013-12-05
US20120214784A1 (en) 2012-08-23
JP2013510870A (ja) 2013-03-28
MX2012005690A (es) 2012-06-13
CA2781041C (en) 2015-01-06
KR101368130B1 (ko) 2014-02-27
EP2501704B1 (en) 2013-09-18
AU2010319400B2 (en) 2013-12-19
EA020391B1 (ru) 2014-10-30
ES2436241T3 (es) 2013-12-27
DK2501704T3 (da) 2013-10-14
CN102666550A (zh) 2012-09-12
CA2781041A1 (en) 2011-05-19
SI2501704T1 (sl) 2013-11-29
PL2501704T3 (pl) 2014-02-28
RS53017B (sr) 2014-04-30
HRP20130969T1 (hr) 2013-11-22
KR20120082927A (ko) 2012-07-24
AU2010319400A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
BRPI0508820B8 (pt) compostos moduladores de receptor de opióide e composição que os compreende
BR112012007102A2 (pt) compostos policíclicos como antagonistas de receptores do ácido lisofosfatpidico
BR112015012555A2 (pt) derivados de benzimidazol como antagonistas de ep4
CY1123365T1 (el) Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
BR112014030060A2 (pt) compostos de tetra-hidropirazolopirimidina
PT2501704E (pt) Compostos de espiropiperidina como antagonistas do receptor orl-1
BR112012024017A2 (pt) compostos derivados de triazina dissubstituída farmaceuticamemnte ativios, composição farmacêutica, método para a síntese destes e uso dos mesmos
BR112014030678A2 (pt) formas cristalinas de um modulador de receptor de androgênio
BR112016009630A8 (pt) receptores de farnesoide x, seus usos, composição farmacêutica, e combinação
PH12012500969A1 (en) Spiropiperidine compounds as orl-1 receptor antagonists
GT201400009A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk
BRPI0808764B8 (pt) compostos espiro-substituídos como inibidores de angiogênese seu processo de produção e composição farmacêutica
BR112013002587A2 (pt) compostos químicos
CL2013001677A1 (es) Compuestos derivados de azabiciclo[3.2.1]octano; agonista del receptor x fernesoide (fxr); proceso para preparar los compuestos; compuesto intermediario; composicion farmaceutica y combinacion farmaceutica que comporenden un compuesto; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de dislipidemia.
BR112013006395A2 (pt) moduladores do receptor de estrogênio e seus usos.
BR112014014184A2 (pt) triazolopiridinas substituídas e seu uso como inibidores de ttk
BR112012013431A2 (pt) composto, composição farmacêutica e seu uso
BR112014011850A8 (pt) Derivados de aminopirimidina, seus usos, e composição farmacêutica
BR112012007234A2 (pt) combinação farmacêutica compreendendo inibidor de dpp-4 e metformina, bem como seu uso e seu processo de preparação
BR112014018475A8 (pt) Compostos de imidazopirrolidinona, suas formas cristalinas e seu uso, e composição farmacêutica
BR112012027197A2 (pt) combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas
CO6592031A2 (es) Nuevos derivados de cocloheliamina que tienen actividad como agonistas adrenérgicos b2 y como antagonistas muscarínicos m3
BRPI0907789A2 (pt) derivaldos 16-alfa e 17-alfa de glicocorticosteroides e seus usos
UY31922A (es) Compuestos
BRPI0900983B8 (pt) composto de diometina, processo para a síntese do mesmo, composição farmacêutica e seu uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time
B350 Update of information on the portal [chapter 15.35 patent gazette]